Updated:
Renhe Capital
Renhe Capital is an investment agency that focuses on private equity investments and private placements in listed companies. The firm has made two investments,...
Renhe Capital
Renhe Capital is an investment agency that focuses on private equity investments and private placements in listed companies. The firm has made two investments, including a seed investment in Biosion on October 29, 2017. Renhe Capital has one portfolio exit, Meidixi Bio, which occurred on November 5, 2019.
General information
Firm type
Private Equity
Location
Region
Asia
Country
China
City
Beijing
Corporate office
Beijing, China
Sector focus
Frequently asked questions
What investment stages does Renhe Capital typically target?
The firm's mandate spans early-stage venture, seed, start-up, expansion and late-stage growth, PIPE transactions, pre-IPO rounds, and restructuring or special situations. This breadth is unusual — most Chinese private equity firms concentrate on a narrower stage band. Whether Renhe actively deploys across all stated stages or maintains the flexibility to pivot is not publicly documented.
Which sectors does Renhe Capital invest in?
The firm's stated sector focus includes enterprise software, artificial intelligence and machine learning, healthcare services, industrial technology, and energy transition and renewables. These align with Chinese government industrial policy priorities in advanced manufacturing, digital economy, and green energy — sectors that have attracted significant domestic private equity activity since 2020.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: